Vestal Point Capital, LP
Q3 2025 13F Holdings
- Locationnew york, NY
- Num holdings
81
- Value ($000)
$2,214,440
- Date Filed11/14/2025
- Form type13F-HR
- CIK0001974915
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
ASND Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | $119.29 M | 5 % | 600,000 | ||
ACLX Arcellx Inc | COMMON STOCK | 03940C100 | $102.63 M | 5 % | 1,250,000 | ||
NUVL Nuvalent Inc | COM | 670703107 | $95.13 M | 4 % | 1,100,000 | ||
Abivax SA | SPONSORED ADS | 00370M103 | $84.90 M | 4 % | 1,000,000 | ||
Alcon AG | ORD SHS | H01301128 | $81.96 M | 4 % | 1,100,000 | ||
Bicara Therapeutics Inc | COM | 055477103 | $80.53 M | 4 % | 5,100,000 | ||
FOLD Amicus Therapeutics Inc | COM | 03152W109 | $76.83 M | 4 % | 9,750,000 | ||
GMED Globus Medical Inc | CL A | 379577208 | $71.59 M | 3 % | 1,250,000 | ||
ISI Ionis Pharmaceuticals Inc | COM | 462222100 | $70.33 M | 3 % | 1,075,000 | ||
Jazz Pharmaceuticals PLC | SHS USD | G50871105 | $65.90 M | 3 % | 500,000 |
Rows Per Page
10
- 10
- 50
- 100